Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013

被引:8
|
作者
Subelj, M. [1 ,2 ]
Ucakar, V. [1 ]
Kraigher, A. [1 ]
Klavs, I. [1 ]
机构
[1] Natl Inst Publ Hlth, Ctr Communicable Dis, Ljubljana, Slovenia
[2] European Ctr Dis Prevent & Control ECDC, EPIET, Stockholm, Sweden
关键词
CERVICAL-CANCER VACCINE; ADOLESCENT GIRLS; CONTROLLED-TRIAL; SAFETY; IMMUNIZATION; IMMUNOGENICITY; SURVEILLANCE; AUTOIMMUNE; PROFILE; ADULTS;
D O I
10.2807/1560-7917.ES.2016.21.14.30187
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Adverse events following immunisation (AEFIs) with qHPV reported to the Slovenian AEFI Registry for the first four school years of the vaccination programme were analysed. We calculated annual reporting rates for 11-14 year-old vaccinees with AEFIs, using the number of qHPV doses distributed within the school-based vaccination programme as the denominator. Between September 2009 and August 2013, 211 AEFIs that occurred in 89 vaccinees were reported, a rate of 149.5 vaccinees with AEFI per 100,000 qHPV doses distributed. For five vaccinees, serious AEFIs (8.4 per 100,000 doses distributed) were reported. The highest reporting rates were for fatigue, headache, and fever (>= 38.0 degrees) (53.8, 40.3, and 35.3 per 100,000 qHPV doses distributed, respectively). As no AEFI resulted in permanent sequelae and they all were categorised as serious only due to the criterion of a minimum of one day of hospitalisation, this provides reassurance for the safety of our school-based HPV vaccination programme. Further AEFI surveillance is warranted to provide data for HPV vaccination programme monitoring and evaluation of its safety.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 40 条
  • [31] Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016)
    Mauro, Alexandre Blikstad
    Fernandes, Eder Gatti
    Miyaji, Karina Takesaki
    Arantes, Benedito Antonio
    Valente, Maria Gomes
    Sato, Helena Keico
    Sartori, Ana Marti C.
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2019, 61
  • [32] Letter to the editor - HPV vaccine and autoimmunity Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study
    Dahan, S.
    Shoenfeld, Y.
    JOURNAL OF INTERNAL MEDICINE, 2017, 281 (03) : 313 - 315
  • [33] Knowledge, perceptions and uptake of human papilloma virus vaccine among adolescent girls in Kampala, Uganda; a mixed-methods school-based study
    Bitariho, Glet Kakuru
    Tuhebwe, Doreen
    Tigaiza, Arnold
    Nalugya, Aisha
    Ssekamatte, Tonny
    Kiwanuka, Suzanne N.
    BMC PEDIATRICS, 2023, 23 (01)
  • [34] Knowledge, perceptions and uptake of human papilloma virus vaccine among adolescent girls in Kampala, Uganda; a mixed-methods school-based study
    Glet Kakuru Bitariho
    Doreen Tuhebwe
    Arnold Tigaiza
    Aisha Nalugya
    Tonny Ssekamatte
    Suzanne N Kiwanuka
    BMC Pediatrics, 23
  • [35] Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study
    Toh, Zheng Quan
    Russell, Fiona M.
    Reyburn, Rita
    Fong, James
    Tuivaga, Evelyn
    Ratu, Tupou
    Nguyen, Cattram D.
    Devi, Rachel
    Kama, Mike
    Matanitobua, Silivia
    Tabrizi, Sepehr N.
    Garland, Suzanne M.
    Sinha, Rohit
    Frazer, Ian
    Tikoduadua, Lisi
    Kado, Joseph
    Rafai, Eric
    Mulholland, Edward K.
    Licciardi, Paul V.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (07) : 852 - 859
  • [36] Mother-Infant Transfer of Anti-Human Papillomavirus (HPV) Antibodies following Vaccination with the Quadrivalent HPV (Type 6/11/16/18) Virus-Like Particle Vaccine
    Matys, Katie
    Mallary, Sara
    Bautista, Oliver
    Vuocolo, Scott
    Manalastas, Ricardo
    Pitisuttithum, Punee
    Saah, Alfred
    CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (06) : 881 - 885
  • [37] Post-approval Safety Monitoring of Quadrivalent and Bivalent Human Papillomavirus Vaccines Based on Real-world Data from the Korea Adverse Events Reporting System (KAERS)
    Kim, MoonJung
    Kim, SangHee
    Shin, Ju-Young
    CLINICAL DRUG INVESTIGATION, 2020, 40 (08) : 727 - 735
  • [38] HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents
    Skinner, S. Rachel
    Davies, Cristyn
    Cooper, Spring
    Stoney, Tanya
    Marshall, Helen
    Jones, Jane
    Collins, Joanne
    Hutton, Heidi
    Parrella, Adriana
    Zimet, Gregory
    Regan, David G.
    Whyte, Patti
    Brotherton, Julia M. L.
    Richmond, Peter
    McCaffrey, Kirsten
    Garland, Suzanne M.
    Leask, Julie
    Kang, Melissa
    Braunack-Mayer, Annette
    Kaldor, John
    McGeechan, Kevin
    BMC PUBLIC HEALTH, 2015, 15
  • [39] Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial
    Pondo, Tracy
    Rose, Charles E., Jr.
    Martin, Stacey W.
    Keitel, Wendy A.
    Keyserling, Harry L.
    Babcock, Janiine
    Parker, Scott
    Jacobson, Robert M.
    Poland, Gregory A.
    McNeil, Michael M.
    VACCINE, 2014, 32 (28) : 3548 - 3554
  • [40] A School-Based Cross-Sectional Survey of Adverse Events following Co-Administration of Albendazole and Praziquantel for Preventive Chemotherapy against Urogenital Schistosomiasis and Soil-Transmitted Helminthiasis in Kwale County, Kenya
    Njenga, Sammy M.
    Ng'ang'a, Paul M.
    Mwanje, Mariam T.
    Bendera, Fatuma S.
    Bockarie, Moses J.
    PLOS ONE, 2014, 9 (02):